To tackle the ongoing high burden of hepatitis C virus (HCV) infections among people who inject drugs (PWID), WHO has set a specific incidence target among PWID of no more than two new infections per ...
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...
Zacks.com on MSN3d
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback